Highest-materiality recent filing
Omnicell Q1 revenue $310M (+15% YoY); raises FY2026 non-GAAP EBITDA/EPS guidance
GAAP net income $11M ($0.25/diluted) vs loss of $7M ($0.15 loss) in Q1 2025.
Omnicell Q4 rev $314M (+2% YoY), GAAP net loss $0.05/sh; FY26 revenue guide $1.215-1.255B
Q4 total revenues $314M (+2% YoY); full-year 2025 rev $1.185B (+7% YoY).
Omnicell launches Titan XT automated dispensing system powered by OmniSphere cloud platform
Launch of Omnicell Titan XT, a next-gen automated dispensing system for autonomous medication management, available now in US.
Omnicell Q3 rev $311M (+10% YoY), beats guidance; raises FY2025 outlook
Q3 revenue $311M (+10% YoY); GAAP EPS $0.12, non-GAAP EPS $0.51; non-GAAP EBITDA $41M.
Omnicell Q2 2025 revenue $291M (+5% YoY), beats guidance; raises FY2025 outlook
Total revenues $291M (+5% YoY); GAAP EPS $0.12, non-GAAP EPS $0.45.
CFO Nchacha Etta to depart; employment extended through Nov 15, 2025, or until successor appointed.
Omnicell raises Q2 and FY2025 profit outlook on tariff relief; authorizes $75M share buyback
Q2 Non-GAAP EBITDA guidance raised to $25-31M (from $22-30M); Non-GAAP EPS raised to $0.24-0.34 (from $0.19-0.32).
Omnicell Q1 revenue $270M (+10% YoY); non-GAAP EPS $0.26 vs $0.03; FY guidance cut
Total revenues $270M, up 10% YoY; GAAP net loss $7M ($0.15) vs loss $16M ($0.34) YoY.
Omnicell Q4 revenue $307M (+19% YoY); 2025 guides ARR $610-630M, product bookings $500-550M
Q4 total revenues $307M, up 19% YoY; GAAP net income $16M ($0.34 diluted) vs loss of $14M in Q4 2023.
Omnicell issues $172.5M 1.00% convertible notes due 2029, repurchases $400M of 2025 notes
Priced $150M (upsized to $172.5M) of 1.00% Convertible Senior Notes due 2029; conversion price ~$57.25 (35% premium).
Omnicell proposes $150M convertible notes due 2029; to repurchase up to $400M of 2025 notes
Offers $150M aggregate principal of 0.25% Convertible Senior Notes due 2029, plus $22.5M greenshoe.
Omnicell Q3 revenue $282M (-5% YoY); raises FY2024 non-GAAP EBITDA & EPS guidance
Q3 GAAP net income $9M ($0.19/diluted) vs. $6M ($0.12) YoY; non-GAAP EPS $0.56 vs. $0.62.
Omnicell Q2 revenue $277M, non-GAAP EPS $0.51; raises FY 2024 guidance
GAAP net income $4M ($0.08 diluted); non-GAAP net income $24M ($0.51 diluted).
Omnicell Q1 revenues down 15% to $246M, GAAP net loss $0.34/sh; initiates wind-down of Medimat RDS
Q1 GAAP revenues $246M (-15% YoY); GAAP net loss $16M ($0.34/sh) vs loss $15M ($0.33/sh) last year.
Omnicell FY2023 rev $1.147B (-11% YoY), GAAP net loss $0.45/sh; FY2024 guidance below prior year
FY2023 total revenue $1.147B, down 11% YoY; GAAP net loss $20M ($0.45/sh) vs prior year GAAP net income $6M.
Omnicell EVP & Chief Commercial Officer Seidelmann departs; $868K severance
Scott P. Seidelmann separated Nov 3, 2023; had transitioned to Special Adviser to CEO on June 1.
Omnicell Q3 rev $299M (-14% YoY); non-GAAP EPS $0.62; cuts FY23 guidance; plans 7% RIF
GAAP revenue $299M (-14% YoY); net income $6M ($0.12 diluted) vs $17M ($0.37) in Q3 2022.
Omnicell CFO Peter Kuipers terminated without cause; severance includes $898K lump sum
CFO Peter J. Kuipers terminated without cause effective Aug 1, 2023; separation agreement signed Aug 4.
Omnicell Q2 revenue $299M (-10% YoY); non-GAAP EPS $0.57 beats guidance; FY outlook $1.16-1.20B
GAAP revenue $299M (-10% YoY); GAAP EPS $0.08; non-GAAP EPS $0.57 (beat guidance).
Omnicell Q1 2023 revenue down 9% YoY to $291M, GAAP net loss of $0.33 per share
Total GAAP revenues $291M (-9% YoY); GAAP net loss $15M ($0.33 loss per share) vs net income $8M ($0.17) prior year.
Omnicell Q4 GAAP loss $0.64; FY2022 revenue up 14%; CFO to step down; cuts 60 jobs
Q4 GAAP net loss $28M ($0.64 loss per share) vs net income $14M ($0.28) in Q4 2021; FY2022 GAAP net income $6M ($0.12) vs $78M ($1.62) in 2021.
Omnicell to cut 9% of workforce (~350 employees) in restructuring plan
Plan approved Nov 23, 2022; reduces headcount by ~350 (9% of total workforce).
Omnicell Q3 revenue $348M (+17% YoY); GAAP EPS $0.37; guides Q4 revenue $285M-$295M
GAAP net income $17M ($0.37/diluted share) vs $29M ($0.61) in Q3 2021.
Omnicell unveils 2025 financial targets: $1.9-2.0B revenue, 23% EBITDA margin
Total revenue target of $1.9-$2.0B by 2025, representing 14-15% CAGR.
Omnicell Q2 revenue up 22% to $331M, non-GAAP EPS $0.84; reaffirms FY guidance; ransomware update
GAAP revenue $331M (+22% YoY); GAAP EPS $0.20 vs $0.43; non-GAAP EPS $0.84 vs $0.97.
On March 12, 2025, Omnicell, Inc. (“Omnicell” or the “Company”) filed a Current Report on Form 8-K disclosing that Nchacha Etta would step down from his role as Executive Vice President, Chief Financial Officer of the Company, effective September 15, 2025 or until a successor is named.
On March 12, 2025, Omnicell, Inc. (the “Company”) announced that Nchacha Etta will step down from his role as Executive Vice President, Chief Financial Officer of the Company, effective September 15, 2025 or until a successor is named.
On September 25, 2024, Omnicell, Inc. (“Omnicell” or the “Company”) announced that Nnamdi Njoku, age 48, has been appointed Executive Vice President and Chief Operating Officer of the Company, effective October 7, 2024.
On February 23, 2024, Joseph B. Spears notified Omnicell, Inc. (the “Company” or “Omnicell”) that he will retire and depart from the Company, effective May 31 , 2024 (the “Spears Retirement Date”).
In addition, effective March 18, 2024, Omnicell has hired Brian Nutt, age 54, to serve as Vice President, Chief Accounting Officer, of the Company.
On January 5, 2024, Sara J. White resigned as a member of the board of directors (the “Board”) of Omnicell, Inc. (the “Company”), including from her position on the Corporate Governance Committee, effective as of January 5, 2024
On January 5, 2024, Vance B. Moore informed the Company that he will not stand for reelection as a Class II director at the 2024 Annual Meeting.
On January 5, 2024, the Board elected Eileen Voynick, effective immediately, to fill the vacancy created by Ms. White’s resignation and to serve as a Class I director with a term expiring at the 2026 annual meeting of stockholders.
Scott P. Seidelmann separated from the Company on November 3, 2023
Ms. Mellon separated from the Company on October 1, 2023
removed Mr. Seim as the Chair and a member of the Audit Committee;
As previously disclosed, Mr. Kuipers was terminated without cause from the Company on August 1, 2023
Max materiality 0.85 · Median 0.57 · Most common event leadership